Intravascular Large B-cell Lymphoma with Bone Marrow Involvement: A Case Successfully Treated with a Rituximab-CHOP Combination Regimen.
10.5045/kjh.2006.41.4.306
- Author:
Tae Hwan LEE
1
;
Eun Kee SONG
Author Information
1. Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea. eksong@chonbuk.ac.kr
- Publication Type:Case Report
- Keywords:
Intravascular large B-cell lymphoma;
Bone marrow;
Rituximab
- MeSH:
Arteries;
B-Lymphocytes*;
Bone Marrow*;
Capillaries;
Diagnosis;
Drug Therapy;
Drug Therapy, Combination;
Early Diagnosis;
Fatal Outcome;
Humans;
Lymphocytes;
Lymphoma, B-Cell*;
Veins;
Rituximab
- From:Korean Journal of Hematology
2006;41(4):306-310
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intravascular large B-cell lymphoma is rare and generally fatal. It is defined pathologically by neoplastic proliferation of lymphoid cells within the lumens of capillaries, small veins, and arteries with little or no other parenchymal involvement. The diagnosis can be delayed because of the rarity of the disease and the difficulty of detection in imaging studies, and a suspicious clinical observation is warranted to make the correct diagnosis. Early diagnosis is important because delayed treatment could result in a fatal outcome. We have encountered a case of intravascular large B-cell lymphoma involving only the bone marrow. An early diagnosis was made and the patient was treated with combination chemotherapy and rituximab targeting CD20. The patient went into complete remission after the third cycle of chemotherapy and maintained a disease free state up to 6 months.
